Capricor Therapeutics (CAPR) Stock: Buy, Sell, or Hold?
$11.22
+2.35 (+26.49%)
▲
5d:
+25.78%
30d:
+63.08%
90d:
+166.51%
Open in Live Scanner
70/30 Portfolio Builder
Earnings: Nov 10, 2026
0d
Protect CAPR Gains
Updated Nov 11, 12:00 AM ET
QUANTITATIVE VERDICT
WAIT
LOW Confidence (29%)
Quality Score
38/100
Position
EXTENDED
30-Day Fair Range
$6.15 – $8.75
Position: EXTENDED
Forward P/E & Valuation
-7.7x
CHEAP
vs 133.6x historical avg
Wall Street Target
$27.00
+140.6% upside
Options IV & Volume
HIGH Vol
HIGH volume confirmation
Support / Resistance
$6.14 / $11.23
Trend: Strong Downtrend
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
⏸️ WAIT FOR BETTER ENTRY: CAPR is 28.2% above its trading range ($8.75). Market expects 0% annual growth, but current price leaves little margin for error. While momentum could continue, risk/reward favors waiting for a pullback.
Smart Money Distribution
Options positioning is turning defensive after a sharp run-up - a pattern consistent with institutional profit-taking. View Scanner →
Signal fired Nov 6, 2026 at $9.01 · last confirmed Nov 11, 2026
Strength: 10.0/10
Get Alerted When CAPR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
In-depth Analysis How we analyze
Valuation Analysis: CAPR is currently trading at $11.22, which is considered extended relative to its 30-day fair value range of $6.15 to $8.75. From a valuation perspective, the stock is trading at a discount (Forward PE: -7.7) compared to its historical average (133.6). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, CAPR is in a strong downtrend. The price is approaching resistance at $11.23. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 26.5% recently.
Market Sentiment: CAPR scores 5/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $27.00 (+140.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CAPR is in a strong downtrend. The price is approaching resistance at $11.23. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 26.5% recently.
Market Sentiment: CAPR scores 5/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $27.00 (+140.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$6.15 -
$8.75
Company Quality Score
38/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
28.6%
Trading Range & Key Levels
30-Day Trading Range
$6.15 -
$8.75
Current vs Trading Range
EXTENDED
Support Level
$6.14
Resistance Level
$11.23
Current Trend
Strong Downtrend
Technical data as of
Nov 11, 2026
Protect Your Profits
Holding CAPR? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanQuantitative Signal Breakdown
- BEARISH: Price significantly overextended (+28.2% above its trading range)
- BEARISH: Weak technical setup (5/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+26.5%)
- BULLISH: Trading 140.6% below Wall St target ($27.00)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- WARNING: Composite score 38/100 in the bottom quintile — this cohort historically lags the market
Fundamental Context
Forward P/E (Next Year Est.)
-7.73
Wall Street Target
$27.00
(+140.6%)
Revenue Growth (YoY)
-7.9%
PE vs Historical
-7.7 vs 133.6
CHEAP
Share CAPR Analysis
Share this live CAPR analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.Reddit & Retail Trader Sentiment (CAPR)
Bullish
28 Retail Mentions
Reddit / WSB Comments
1
Bearish
StockTwits Volume
27 msgs
24h retail stream
Last Tracked
Nov 12, 2026
Daily AI digest
AI Retail Discussion Summary:
Capricor Therapeutics' ($CAPR) stock rallied as investors awaited the FDA's decision on Deramiocel for Duchenne muscular dystrophy. Traders expressed optimism about the impending approval and potential profit-taking.
Key Retail Themes:
FDA decision
Profit-taking
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams.
View All Trending Reddit & WSB Stocks →
Last updated: November 12, 2026 2:45 AM ET
Data refreshes hourly during market hours. Next update: 3:45 AM
Data refreshes hourly during market hours. Next update: 3:45 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CAPR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
VRTX
Vertex Pharmaceuticals I… |
STRONG BUY
32 analysts |
$592 | 44 HOLD |
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$302 | 55 HOLD |
|
ONC
BeOne Medicines AG |
STRONG BUY
27 analysts |
$438 | 35 SELL |
|
ORIC
Oric Pharmaceuticals Inc |
STRONG BUY
15 analysts |
$22 | 67 BUY |
|
TVTX
Travere Therapeutics Inc |
STRONG BUY
15 analysts |
$75 | 66 BUY |
Advanced CAPR Option Strategies
Professional options setups generated by AI based on today's CAPR price and gamma walls.
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive CAPR Research Pages
